Molecular Formula | C27H35N3O5 |
Molar Mass | 481.58 |
Density | 1.24±0.1 g/cm3(Predicted) |
Boling Point | 641.8±55.0 °C(Predicted) |
Solubility | DMSO |
pKa | 10.68±0.20(Predicted) |
Storage Condition | -20℃ |
In vitro study | Exposure to 1 μM TPOP146 results in a significant decrease of recovery half-life that is comparable to the construct that contained the bromodomain inactivating mutation N1168F, demonstrating that TPOP146 targets the CBP bromodomain in the nucleus and is capable of competing with acetyl-lysine mediated interactions of the CBP bromodomain in cellular environments. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.076 ml | 10.382 ml | 20.765 ml |
5 mM | 0.415 ml | 2.076 ml | 4.153 ml |
10 mM | 0.208 ml | 1.038 ml | 2.076 ml |
5 mM | 0.042 ml | 0.208 ml | 0.415 ml |
biological activity | TPOP146 is a selective CBP/P300 benzodiazepam domain inhibitor; the Kd values for CBP and BRD4 were 134 nM and 5.02 μm, respectively. |
Target | IC50: 134 nM (CBP); 5.02 μm (BRD4) |